ICYMI: aTyr Investors — mark your calendars

The law firm Faruqi & Faruqi, LLP is reminding shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) about the upcoming deadline of December 8, 2025 to seek the role of lead plaintiff in a pending federal securities class‑action lawsuit. According to Faruqi & Faruqi, the complaint alleges that aTyr and certain executives misled investors by issuing overly optimistic statements about the drug efzofitimod — particularly regarding its ability to allow patients to fully taper off steroid use — while allegedly hiding material information about the drug’s actual efficacy. In a pivotal trial (the “EFZO‑FIT” study), efzofitimod reportedly failed to produce a significant change in mean daily oral corticosteroid dose by week 48. On average, patients receiving 5.0 mg/kg saw a reduction of 2.79 mg, compared with a 3.52 mg reduction in the placebo group; complete steroid withdrawal was achieved by 52.6% of treated patients vs. 40.2% in placebo — a difference Faruqi & Faruqi argue does not support prior public claims. When the results were released, aTyr’s share price plunged by 83.25%, falling from a close of $6.03 on September 12, 2025, to $1.01 on September 15. Investors who purchased or acquired aTyr securities between January 16, 2025 and September 12, 2025 and experienced losses may contact Faruqi & Faruqi — specifically partner James (Josh) Wilson — to discuss legal options. The firm also welcomes information from whistleblowers, former employees, shareholders, and others with relevant knowledge. #aTyr #ClassAction #efzofitimod #InvestorAlert #SlimScan #GrowthStocks #CANSLIM